Adma Biologics Inc Revenue Growth Rates (ADMA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Adma Biologics Inc   (NASDAQ: ADMA)
 

ADMA's Revenue Growth by Quarter and Year

Adma Biologics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ADMA/growth
https://api.csimarket.com/api/v1/companies/ADMA/fundamentals
https://api.csimarket.com/api/v1/companies/ADMA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ADMA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 141.10
2nd Quarter June 124.40
1st Quarter March 113.75
FY 379.25

ADMAs Annual Revenue
Adma Biologics Inc 's Revenue in the fiscal year 2025 $ 510.17 millions
Adma Biologics Inc 's Revenue in the fiscal year 2024 $ 425.55 millions
Adma Biologics Inc 's Revenue in the fiscal year 2023 $ 257.94 millions
Adma Biologics Inc 's Revenue in the fiscal year 2022 $ 154.08 millions
Adma Biologics Inc 's Revenue in the fiscal year 2021 $ 80.94 millions




ADMA Revenue third quarter 2026 Y/Y Growth Comment
Adma Biologics Inc reported Revenue growth of 5.59% year on year in the third quarter 2026, to $ 141.10 millions, this is lower than Adma Biologics Inc 's recent average Revenue surge of 393.58%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 41 other companies have achieved higher Revenue growth. While Adma Biologics Inc ' s Revenue increase of 5.59% ranks overall at the positon no. 2530 in the third quarter 2026.


ADMA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.59 %
2nd Quarter June 2.61 %
1st Quarter March -0.31 %
FY   -

Financial Statements
Adma Biologics Inc 's third quarter 2026 Revenue $ 141.10 millions ADMA's Income Statement
Adma Biologics Inc 's third quarter 2025 Revenue $ 133.63 millions Quarterly ADMA's Income Statement


ADMA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 13.43 %
2nd Quarter June 9.36 %
1st Quarter March -18.26 %
FY (Year on Year)   -


Back to ADMA Growth rate Comparisons >> Back to ADMA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #42
Healthcare Sector #364
Overall #2530

Revenue Y/Y Growth Statistics
High Average Low
17921.25 % 393.58 % -66.2 %
(Dec 31 2013)   (Mar 31 2019)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #42
Healthcare Sector #364
Overall #2530
Revenue Y/Y Growth Statistics
High Average Low
17921.25 % 393.58 % -66.2 %
(Dec 31 2013)   (Mar 31 2019)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Adma Biologics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
5129.45 % 107.1 % -66.32 %
(Jun 30 2012)  


ADMA's III. Quarter Q/Q Revenue Comment
Adma Biologics Inc achieved in the III. Quarter 2026 below company average Revenue rise of 13.43% quarter on quarter, to $ 141.10 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 10.23% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Adma Biologics Inc 's Revenue growth quarter on quarter, overall rank is 706.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #118
Overall #706
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #118
Overall #706
Revenue Q/Q Growth Statistics
High Average Low
5129.45 % 107.1 % -66.32 %
(Jun 30 2012)  


ADMA's III. Quarter Q/Q Revenue Comment
Adma Biologics Inc achieved in the III. Quarter 2026 below company average Revenue rise of 13.43% quarter on quarter, to $ 141.10 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 10.23% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Adma Biologics Inc 's Revenue growth quarter on quarter, overall rank is 706.


Adma Biologics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 510.93
Y / Y Revenue Growth (TTM) 8.13 %
Year on Year Revenue Growth Overall Ranking # 385
Seqeuential Revenue Change (TTM) 0.62 %
Seq. Revenue Growth (TTM) Overall Ranking # 2271


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Adma Biologics Inc 's cumulative twelve months Revenue were $ 511 millions, company would post below average annual Revenue growth of 0.62% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Adma Biologics Inc 's Revenue growth from the 124.4% growth in Mar 31 2026.

In the Healthcare sector 98 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 148 to 385.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 39
Healthcare Sector # 99
Overall # 385

Revenue TTM Y/Y Growth Statistics
High Average Low
187.12 %
 57.67 %
-31.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 331
S&P 500 # 2271
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Adma Biologics Inc 's cumulative twelve months Revenue were $ 511 millions, company would post below average annual Revenue growth of -31.86% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Adma Biologics Inc 's Revenue growth from the 124.4% growth in Mar 31 2026.

In the Healthcare sector 98 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 148 to 385.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 39
Healthcare Sector # 99
Overall # 385

Revenue TTM Y/Y Growth Statistics
High Average Low
187.12 %
57.67 %
-31.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 331
S&P 500 # 2271




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADMA's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Bausch Health Companies Inc 9.70%$ 9.698 millions
Marpai Inc9.59%$ 9.586 millions
Haemonetics Corporation9.49%$ 9.492 millions
Progyny Inc 9.08%$ 9.084 millions
Ironwood Pharmaceuticals inc 9.00%$ 8.996 millions
Encompass Health Corporation8.93%$ 8.934 millions
West Pharmaceutical Services Inc 8.73%$ 8.728 millions
Resmed Inc 8.67%$ 8.667 millions
Carlisle Companies Incorporated8.65%$ 8.649 millions
Concentra Group Holdings Parent Inc 8.61%$ 8.611 millions
Merit Medical Systems Inc8.56%$ 8.563 millions
Medpace Holdings Inc 8.50%$ 8.501 millions
Pulmonx Corporation8.47%$ 8.470 millions
Amgen Inc 8.45%$ 8.455 millions
Precipio inc 8.33%$ 8.335 millions
Fulgent Genetics Inc 8.26%$ 8.262 millions
Amphastar Pharmaceuticals Inc 8.22%$ 8.219 millions
Ultragenyx Pharmaceutical Inc 8.17%$ 8.170 millions
Baxter International Inc 8.08%$ 8.078 millions
Tactile Systems Technology Inc 8.07%$ 8.067 millions
Iqvia Holdings Inc 8.00%$ 8.000 millions
Exagen Inc 7.86%$ 7.859 millions
Gyre Therapeutics Inc 7.75%$ 7.754 millions
Stryker Corp7.64%$ 7.644 millions
Bausch and Lomb Corp7.34%$ 7.338 millions
Addus Homecare Corp7.19%$ 7.193 millions
Pacific Biosciences Of California Inc 7.03%$ 7.026 millions
Bristol myers Squibb Company6.93%$ 6.930 millions
Labcorp Holdings Inc 6.92%$ 6.917 millions
Gilead Sciences Inc 6.83%$ 6.835 millions


About Adma Biologics Inc Revenue Growth Rates (ADMA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Adma Biologics Inc (CIK 1368514).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001140361-26-041977
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Adma Biologics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.